Occult prostate cancer in men with low serum testosterone levels

JAMA

Volumn 276, Issue 23, 1996, Pages 1904-1906

  Morgentaler, Abraham ^a,b   Bruning III, Carl O ^a   DeWolf, William C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCULT CANCER; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RETROSPECTIVE STUDY; TRANSRECTAL ULTRASONOGRAPHY;

EID: 0029856354     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.276.23.1904     Document Type: Article

References (24)

1. Rudman D, Shetty KR. Unanswered questions concerning the treatment of hyposomatotropism and hypogonadism in elderly men. J Am Geriatr Soc. 1994;42:522-527.
2. English HG, Kloszewski ED, Valentine EC, Santen RJ. Proliferative response of the Dunning R3327-H experimental model of prostatic adenocarcinoma to conditions of androgen depletion and repletion. Cancer Res. 1986;46:839-844.
3. Jackson JA, Waxman J, Spiekerman AM. Prostatic complications of testosterone replacement therapy. Arch, Intern Med. 1989;149:2365-2366.
4. Tenover JS. Androgen administration to aging men. Endocrinol Metab Clin North Am. 1994;23: 877-892.
5. Brawer MK, Daum P, Petteway JC, Wener MH. Assay variability in serum PSA determination. Prostate. 1995;27:1-6.
6. Gleason DF, Veterans Administration Cooperative Urologicäl Research Group. Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, ed. Urologic Pathology: The Prostate. Philadelphia. Pa: Lea & Febiger: 1977.
7. Labrie F, Dupont A, Suburu A, et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol. 1992;147:846-851.
8. Cooner WH, Mosley BR, Rutherford CL Jr, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination, and prostate-specific antigen. J Urol. 1990; 143:1146-1150.
9. Seaman E, Whang M, Olsson CA, Katz A, Cooner WH, Benson MC. PSA density (PSAD). Urol Clin North Am. 1993;20:653-663.
10. Vallancien G, Prapotnich D, Veillon B, Brisset JM, Andre-Bougaran J. Systematic prostatic biopsies in 100 men with no suspicion of cancer on digital rectal examination. J Urol. 1991;146:1308-1312.
11. Ellis WJ, Chetner M, Preston S, Brawer MK. Diagnosis of prostatic carcinoma: the yield of serum PSA, DRE, and TRUS. J Urol. 1994;152:1520-1525.
12. Hammerer P, Loy V, Huland H. Prostate cancer in nonneurological patients with normal prostates on digital rectal examination. J Urol. 1992; 147:833-836.
13. Stone NN, DeAntoni EP, Crawford E. Screening for prostate cancer by digital rectal examination and prostate-specific antigen: results of Prostate Cancer Awareness Week, 1989-1992. Urology. 1994;44(6A):18-25.
14. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156-1161.
15. Uzzo RG, Wei JT, Waldbaum RS, Perlmutter AP, Byrne JC, Vaughan ED Jr. The influence of prostate size on cancer detection. Urology. 1995; 46:831-836.
16. Billis A. Latent carcinoma and atypical lesions of prostate. Urology. 1986;28:324-329.
17. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909-916.
18. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab. 1992;75:1092-1098.
19. Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone treated and untreated hypogonadal men in comparison to age matched normal controls. Clin Endocrinol. 1994;40:341-349.
20. Meshref AW, Bazinet M, Trudel C, et al. Role of prostate-specific antigen density after applying age-specific prostate-specific antigen reference ranges. Urology. 1995;45:972-979.
21. Monath JR, McCullough DL, Hart LJ, Jarow JP. Physiologic variations of serum testosterone within the normal range do not affect serum prostate-specific antigen. Urology. 1995;46:58-61.
22. Monda JM, Myers RP, Bostwick DG, Oesterling JE. The correlation between serum prostate-specific antigen and prostate cancer is not influenced by the serum testosterone concentration. Urology. 1995;46:62-64.
23. Stamey TA, Kabalin JN, Ferrari M, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate, IV: antiandrogen treated patienta. J Urol. 1989;141:1088-1090.
24. Guess HA, Heyse JF, Gormley GJ, Stoner E, Oesterling JE. Effect of finasteride on serum PSA concentration in men with benign prostatic hypertrophy. Urol Clin North Am. 1993;20:627-636.